VahatiCor Enrolls First U.S. Patient in SERRA-I Clinical Study of A-FLUX Reducer System® for CMD

Contributed by: PR Newswire

Tags

VahatiCorFirstPatient

More Like This

VahatiCor CEO, Harry D. Rowland, Ph.D.

VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer

CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership

Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt

Corvia's RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data

PR Newswire associated0

Adagio Medical Announces Initiation and First Procedure in FULCRUM-VT Trial, Starting The Process For Bringing Ultra-Low Temperature Cryoablation for Ventricular Arrhythmias to US Market

Reflow Medical Enrolls First Patients in Pilot Study of Coronary Sirolimus-Eluting Retrievable Scaffold System (Spur Elute)

CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients